Recon: Top EU court favors Illumina over EU regulators in Grail deal; US will still pay more for drugs than its peers after Medicare price negotiations

• Letting funding for the All of Us research program lapse will cost the U.S. far more than it saves (STAT)
• FDA authorizes Novavax's updated COVID vaccine targeting JN.1 strain (Reuters)
• Emergent Bio's smallpox vaccine gets US approval for mpox (Reuters)
• At major cardiology conference, Wegovy’s the word (STAT)
• The alliance between RFK Jr. and Trump all comes down to their health-related worldview (STAT)
• Updated: Vaxcyte surges on Phase 1/2 data for 31-valent pneumococcal vaccine (Endpoints)
• Exclusive: Duke spinout launches in hopes of prevailing with brain cancer bispecific where Amgen, Roche did not (Endpoints)
• Rules? Where We’re Going, We Don’t Need Rules: FDA Goes Back to the Future With Recent Hatch-Waxman Policy Shifts; What’s a Company to do? (FDA Law Blog)
• US will still pay at least twice as much after negotiating drug prices (Reuters)
• Semnur Pharmaceuticals to go public via SPAC merger with Denali Capital in $2.5 bln deal (Reuters)

• UK government partners with pharma on new £400M life science infusion (Endpoints)
• European court sides with Illumina, saying regulators overstepped in scrutiny of Grail deal (STAT) (Reuters)
• Novo Nordisk continues to grapple with patchy GLP-1 drug supply in Europe (Endpoints)
• EU-US-Japanese-Indian Pharmacopeia Group Says ‘New Members Wanted’ (Pink Sheet)
• Pharma Firms To Benefit From New UK Hub-And-Spoke Clinical Trial Network (Pink Sheet)
• African drugmaker Aspen in talks to manufacture mpox vaccines (Reuters)
• Mpox vaccines to arrive in DR Congo in next few days, WHO says (Reuters)
• Japan Prepares For Mpox Vaccine Donation (Pink Sheet)
• UK Regulator Explains Changes To Pharmacovigilance Rules From 2025 (Pink Sheet)

• Sanofi says its new pill for multiple sclerosis succeeded in a key trial, boosting its research ambitions (STAT)
• Recursion presents mixed data on lead AI-derived drug candidate for potentially fatal brain condition (STAT) (Reuters)
• Alnylam shares slide after heart drug data fails to impress investors (Reuters)
• Three Dyne executives leave as company reports new Duchenne drug data (Endpoints)
• Praxis' epilepsy drug reduces seizures by 46% in pediatric patients in Phase 2 study (Endpoints)
• Denali details accelerated approval plans; Jazz's $850M private offering (Endpoints)
• ProKidney axes one Phase 3 study, aims for 'expedited approval pathway' using another (Endpoints)
• Exclusive: PatientPartner raises $7M to help pharma companies match patients with mentors (Endpoints)
• Arrowhead spotlights key pancreatitis figures from Phase 3 lipid disease study to differentiate itself from Ionis (Endpoints)
• Springer Nature could launch IPO as soon as next week, sources say (Reuters)

• Explore the clinical tools that use race to steer care (STAT)
• Embecta gets FDA nod for insulin patch pump (MedTech Dive)
• ARPA-H program to focus on AI degradation in medical tools (MedTech Dive)
• Medtronic’s chief medical officer of acute care and monitoring departs for new role (MedTech Dive)
• Pathology group sues to block FDA lab test rule (MedTech Dive)
• FDA finalizes Voluntary Malfunction Summary Reporting guidance (MedTech Dive)
• FDA Announces Four New Device Classifications (MedTech Insight)
• Renata Medical Headed To Market With Stent For Children With Congenital Heart Defects (MedTech Insight)

• Doctors use problematic race-based algorithms to guide care every day. Why are they so hard to change? (STAT)
• Diagnosed with cancer, a pharmaceutical executive became a patient advocate and changed drug development. It took decades (STAT)
• Drug distributors strike $300 mln opioid settlement with US health plans (Reuters)